生物膜修改的普鲁士蓝色改善了阿尔茨海默病晚期阶段小鼠的记忆功能,并进行了三重疗法
Lianxin Li1, Jiayang Zhang1, Yuewen Zhang1
1School of Pharmacy, Jiangsu University, Zhenjiang, Jiangsu 212013, PR China.
International journal of pharmaceutics
|December 28, 2024
概括
这项研究引入了一种新型纳米材料,即涂有巨细胞膜 (PB NPs/MM) 的普鲁士蓝色纳米粒子,用于治疗阿尔茨海默病 (AD). 这种创新方法有效地减少了粉样β聚合,并改善了小鼠的认知功能.
科学领域:
- 神经科学是一个神经科学.
- 材料科学 材料科学 材料科学
- 纳米技术纳米技术
背景情况:
- 阿尔茨海默病 (AD) 涉及认知衰退,金属离子障碍和氧化应激,导致粉样β (Aβ) 聚合.
- 现有的治疗方法在准大脑和管理复杂的病理因素方面面临挑战.
研究的目的:
- 开发一种用于治疗晚期阿尔茨海默病的多功能纳米材料.
- 为了研究巨细胞膜涂层的普鲁士蓝色纳米粒子 (PB NPs/MM) 在解决Aβ聚合,氧化应激和认知缺陷方面的有效性.
主要方法:
- 设计的PB NPs/MM复合纳米材料用于增强血脑屏障 (BBB) 透和治疗向.
- 使用PBNP用于Cu2+化和ROS清理,与光热疗法相结合.
- 在APP/PS1小鼠体内评估了Aβ聚合的 in vitro抑制和体内认知改善.
主要成果:
- PB NPs/MM有效抑制了Cu2+诱导的Aβ聚合和光热去聚合的Aβ纤维.
- 该纳米材料减轻了氧化应激,并在近红外激光照射下证明了改善的BBB传输.
- 在接受治疗的小鼠中观察到认知和学习缺陷的显著改善.
结论:
- PB NPs/MM是阿尔茨海默病治疗的有前途的多功能纳米系统.
- 金属化,光热疗法和ROS清理的综合方法为神经退行性疾病治疗提供了一种新的策略.
更多相关视频
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
42.0K
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.2K
相关概念视频
01:22Alzheimer's Disease: Treatment
162
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
162
01:26Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444